ORCID
- Jarvis, Michael: 0000-0002-0124-4061
Abstract
AbstractEbolaviruses pose significant public health problems due to their high lethality, unpredictable emergence, and localization to the poorest areas of the world. In addition to implementation of standard public health control procedures, a number of experimental human vaccines are being explored as a further means for outbreak control. Recombinant cytomegalovirus (CMV)-based vectors are a novel vaccine platform that have been shown to induce substantial levels of durable, but primarily T-cell-biased responses against the encoded heterologous target antigen. Herein, we demonstrate the ability of rhesus CMV (RhCMV) expressing Ebola virus (EBOV) glycoprotein (GP) to provide protective immunity to rhesus macaques against lethal EBOV challenge. Surprisingly, vaccination was associated with high levels of GP-specific antibodies, but with no detectable GP-directed cellular immunity.
DOI
10.1038/srep21674
Publication Date
2016-02-15
Publication Title
Scientific Reports
Volume
6
Issue
1
ISSN
2045-2322
Organisational Unit
School of Biomedical Sciences
Recommended Citation
Marzi, A., Murphy, A., Feldmann, F., Parkins, C., Haddock, E., Hanley, P., Emery, M., Engelmann, F., Messaoudi, I., Feldmann, H., & Jarvis, M. (2016) 'Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection', Scientific Reports, 6(1). Available at: https://doi.org/10.1038/srep21674
